PAHCNasdaqPharmaceutical PreparationsFiscal year ends June 30
PHIBRO ANIMAL HEALTH CORP
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 26, 2026
$39.34+0.52 (+1.34%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- 16.2
- Dividend yield
- 1.22%
PHIBRO ANIMAL HEALTH CORP revenue by segment
By business segment
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Animal Health | $1.16B | $1.16B | $1.12B | $1.06B | $962.80M | $861.83M | $784.79M | $728.48M | $706.48M | $691.72M | $674.82M | $665.52M | 76.6% | +20.7% |
| Mineral Nutrition | $282.34M | $269.51M | $262.86M | $257.17M | $253.24M | $251.15M | $248.60M | $246.70M | $243.66M | $240.05M | $238.74M | $239.04M | 18.6% | +11.5% |
| Performance Products | $73.53M | $73.40M | $77.18M | $78.78M | $80.18M | $77.70M | $72.69M | $71.59M | $67.53M | $67.80M | $68.45M | $72.16M | 4.8% | -8.3% |
By product or service
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Animal Health | $1.16B | $1.16B | $1.12B | $1.06B | $962.80M | $861.83M | $784.79M | $728.48M | $706.48M | $691.72M | $674.82M | $665.52M | 76.6% | +20.7% |
| MFAs and other | $810.73M | $809.63M | $785.48M | $733.71M | $646.35M | $556.53M | $483.10M | $434.70M | $420.96M | $408.42M | $393.43M | $388.66M | 53.4% | +25.4% |
| Mineral Nutrition | $282.34M | $269.51M | $262.86M | $257.17M | $253.24M | $251.15M | $248.60M | $246.70M | $243.66M | $240.05M | $238.74M | $239.04M | 18.6% | +11.5% |
| Nutritional Specialties | $195.07M | $192.57M | $189.11M | $184.79M | $179.29M | $174.74M | $171.58M | $167.11M | $164.67M | $166.42M | $171.24M | $173.66M | 12.8% | +8.8% |
| Vaccines | $156.42M | $154.94M | $149.70M | $145.23M | $137.15M | $130.57M | $130.11M | $126.67M | $120.85M | $116.88M | $110.16M | $103.20M | 10.3% | +14.0% |
| Performance Products | $73.53M | $73.40M | $77.18M | $78.78M | $80.18M | $77.70M | $72.69M | $71.59M | $67.53M | $67.80M | $68.45M | $72.16M | 4.8% | -8.3% |
By region
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $877.13M | $858.86M | $836.03M | $798.72M | $739.92M | $691.61M | $640.98M | $597.03M | $584.76M | $576.14M | $565.36M | $574.26M | 57.8% | +18.5% |
| Latin America and Canada | $340.67M | $334.52M | $329.65M | $314.72M | $298.65M | $284.74M | $267.64M | $260.15M | $247.71M | $237.44M | $237.67M | $226.30M | 22.4% | +14.1% |
| Europe, Middle East and Africa | $187.94M | $191.80M | $186.24M | $174.05M | $160.23M | $135.03M | $129.29M | $126.22M | $121.98M | $121.87M | $116.87M | $115.18M | 12.4% | +17.3% |
| Asia Pacific | $112.36M | $114.86M | $112.40M | $112.19M | $97.42M | $79.30M | $68.16M | $63.36M | $63.23M | $64.12M | $62.12M | $60.98M | 7.4% | +15.3% |
From the segment and revenue-disaggregation notes of Phibro Animal Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.